NCT04651127 2026-03-10
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
Sun Yat-sen University
Phase 1/2 Terminated
Clinical Trials
9 trialsNCT07412262 2026-02-17
A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer With Acquired Resistance to Immunotherapy and High YAP Protein Expression
Guangdong Association of Clinical Trials
Phase 2 Not yet recruiting
NCT07397832 2026-02-09
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06951997 2026-01-26
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT07339527 2026-01-14
EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT06776952 2026-01-09
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Evopoint Biosciences Inc.
Phase 3 Recruiting
NCT07093710 2025-12-31
Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
Sun Yat-sen University
Phase 1/2 Recruiting
NCT07304232 2025-12-26
CM-AML-001
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT05141357 2025-12-24
HBI-8000
HUYABIO International, LLC.
Phase 2 Terminated